Takeda auctions off a $670M portfolio of drugs and manufacturing ops, getting closer to its $10B goal
Takeda is $670 million closer to its goal of selling off $10 billion in assets to help pay for the Shire buyout.
The pharma giant reported Friday that it has sold off a portfolio of drugs and a pair of European manufacturing sites to Denmark’s Orifarm Group. The latest in a string of auctions, capped by the $5.3 billion sale of Xiidra to Novartis, Takeda has been systematically auctioning off bits of the company to pay down debt built in the acquisition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.